Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in India

Last updated: December 20, 2024
Sponsor: Boston University
Overall Status: Active - Recruiting

Phase

N/A

Condition

Influenza

Covid-19

Corona Virus

Treatment

Exposures

Clinical Study ID

NCT06168019
H-43541
UG1HD078439
  • Ages 18-50
  • Female

Study Summary

This study will be conducted as a prospective cohort study, enrolling all eligible women in their first trimester of pregnancy during a baseline visit during week 6-13 of pregnancy at Government Medical College Hospital, Nagpur. The Hospital provides primary, secondary, and tertiary care and the obstetric department delivers about 10,000 babies a year. The hypothesis is that co-infection of other respiratory viruses (ORV), particularly COVID-19 and Influenza increases the risk of adverse pregnancy outcomes in mothers and babies and could address the current standard of care in India to not vaccinate pregnant women during pregnancy, by either encouraging vaccination against both viruses before planning a pregnancy or during pregnancy based on global data supporting the safety of this strategy.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Women aged 18 to 50 years registering for antenatal care (ANC) at Government Medical College Hospital (GMC) Nagpur, India

  • Estimated Gestational Age at registration <14 weeks based on ultrasound report atthe baseline study visit;

  • Intends to receive pregnancy, labor and delivery and neonatal care at GMC;

  • Plans to live within the city limits of Nagpur throughout their pregnancy and laborand delivery to facilitate access to GMC for evaluation of ILI and COVID-19symptoms;

  • Willing to be contacted two times per week by call or text for ILI/ COVID-19 symptomscreening and return to GMC for evaluation and an NP swab/evaluation if symptoms arereported;

  • Willing to take temperature with the provided digital thermometer, and maintain asymptom diary after training;

  • Willing to provide information on pregnancy and neonatal outcomes if care occursoutside GMC;

  • Willing to permit venous blood draws on at least 4 timepoints --1) Baseline studyvisit, 2)28-34 weeks, 3) 37 weeks - prior to delivery and 4) after delivery;

  • Willing to permit blood draws if hospitalized at GMC for COVID-19 infection;

  • Willing to consent to participate in the study

Exclusion

Exclusion Criteria:

  • Anyone who is deemed to have limited decision-making capacity as defined by BostonUniversity IRB i.e. Substantial impairment of cognitive functions (e.g. attention,comprehension, memory, and intellect), or conditions that might affect theircognitive functions.

  • Anyone who is deemed to have limited capacity to consent as defined by BostonUniversity Institutional Review Board (IRB) i.e. The ability to provide legallyeffective consent to enroll in a research study (AAHRPP definition).

Study Design

Total Participants: 10000
Treatment Group(s): 1
Primary Treatment: Exposures
Phase:
Study Start date:
December 26, 2023
Estimated Completion Date:
June 30, 2028

Study Description

All pregnant women enrolled in the study will receive standard of care throughout their pregnancy, labor and delivery and post-partum to discharge. Wherever possible, study visits will coincide with regular antenatal (ANC) care and blood draws will be added to standard blood draws during ANC, labor and delivery and postpartum care. Women will be counselled about procedure to reduce the risk of acquiring ORV during pregnancy. Since this study is observational, we do not anticipate any specific safety concerns with study interviews and procedures, but the investigators will monitor potential adverse events to determine if they are likely or possibly study related.

PRIMARY OBJECTIVE: Determine the prevalence, incidence, and maximal severity of symptomatic or asymptomatic COVID-19 in pregnant women to day 42 postpartum/after miscarriage on maternal outcomes. Secondary analysis will evaluate whether influenza/Other Respiratory Viruses (ORV) infection or COVID-19 vaccination modifies or mediates this risk.

SECONDARY OBJECTIVE: Determine the effect of maternal COVID-19 infection on the fetus and/or neonate during pregnancy through day 7 of life. Secondary analysis will focus on whether influenza/ORV or vaccination modifies, and pre-term birth mediates this risk.

EXPLORATORY OBJECTIVE: Characterize patterns and trajectories of host response/ inflammatory biomarkers as potential mediators of COVID-19 ± Influenza and ORV infection on progression to severe illness in pregnant women/mothers admitted to Government Medical College hospital with COVID-19. Modifiers include COVID-19 , Influenza and other ORV vaccinations.

Connect with a study center

  • Government. Medical College Hospital

    Nagpur,
    India

    Active - Recruiting

  • Boston University School of Public Health, Global Health

    Boston, Massachusetts 02118
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.